Group 1 - The AACR conference is expected to catalyze data for innovative drugs, with over 100 Chinese pharmaceutical companies presenting nearly 400 research results, enhancing the visibility of companies like HengRui, BeiGene, and others in key therapeutic areas [4][7] - The conference is likely to boost sentiment in the innovative drug sector, as China has shown stable output in multiple mainstream tracks, including ADCs and dual antibodies, indicating a significant presence and engagement in academic discussions [7] - The oral GLP-1 receptor agonist Orforglipron is anticipated to be approved in Q2 2026, marking a shift to oral weight-loss medications, which could significantly expand the patient population and create substantial investment opportunities in the supply chain [8] Group 2 - The pharmaceutical and biotechnology sector's TTM-PE is at 44.16 times, representing a 217% premium over the CSI 300, indicating a reasonable valuation compared to historical lows [9] - The healthcare sector has shown a mixed performance, with the pharmaceutical sector rising by 1.56%, ranking fourth among 27 sub-industries, while chemical raw materials and medical services saw significant gains [13][16] - Individual stock performance highlights include notable gains for Meinuohua (40.73%) and Fuxiang Pharmaceutical (27.61%), while Jichuan Pharmaceutical and Baiyunshan experienced declines [19][22] Group 3 - Recent industry dynamics include Novo Nordisk's approval of a weekly long-acting insulin in the U.S., and Haihe Pharmaceutical's selective PI3Kα inhibitor receiving approval in Japan, showcasing ongoing innovation in diabetes and cancer treatments [20][21] - Corcept Therapeutics' approval of a new ovarian cancer drug in the U.S. and Ionis' submission for a rare disease treatment reflect the active pipeline in oncology and rare diseases [24][25] - GSK's long-acting monoclonal antibody for asthma and the approval of a new eye treatment by Yuanda Pharmaceutical demonstrate the expanding therapeutic options in respiratory and ophthalmic care [32][33]

Investment Rating - The report maintains a "Recommended" rating for the company Fuhong Hanlin (stock code: 2696.HK) [1] Core Insights - Fuhong Hanlin reported a revenue of 6.667 billion yuan for 2025, representing a year-on-year growth of 16.5%, and a net profit of 827 million yuan, with a slight increase of 0.8% [4] - The company has achieved continuous revenue and profit growth for three consecutive years since it first became profitable in 2023 [4] - The global product revenue reached 5.775 billion yuan, with a year-on-year increase of 17.0%, driven by significant sales of core products [4] - The company’s R&D investment for the year was 2.492 billion yuan, reflecting a 35.4% increase year-on-year [4] - The report highlights the successful internationalization of core products, particularly HLX43 and trastuzumab, which have seen substantial overseas sales growth [4] Financial Performance Summary - The company’s projected financial performance for 2026-2028 includes: - Revenue: 8.059 billion yuan in 2026, 7.786 billion yuan in 2027, and 9.486 billion yuan in 2028 - Net profit: 1.018 billion yuan in 2026, 982 million yuan in 2027, and 1.255 billion yuan in 2028 - The projected PE ratios are 34, 36, and 28 for the years 2026, 2027, and 2028 respectively [5] - The gross margin is expected to remain strong, with estimates of 76.43% in 2026 and 74.98% in 2027 and 2028 [5] Product and Market Development - The report emphasizes the global sales performance of key products: - Sales of HLX43 reached 1.493 billion yuan, with a year-on-year growth of 13.7% - Trastuzumab sales amounted to 2.9645 billion yuan, showing a 5.5% increase, and it is now included in multiple national insurance systems [4] - The sales of neratinib surged by 564.2% to 301.2 million yuan, solidifying its position in the HER2-positive early breast cancer treatment market [4] - The company is actively exploring the potential of its innovative pipeline, including ADC and monoclonal antibodies, with promising data presented at international academic conferences [4]

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" for the biopharmaceutical sector [7] Core Insights - The report highlights the upcoming European Lung Cancer Conference (ELCC 2026) scheduled for March 25-28, 2026, in Copenhagen, Denmark, where significant data disclosures are expected from domestic companies [3][24] - Notable clinical trial results have been reported, including the final overall survival (OS) data for科伦博泰's TROP2 ADC sac-TMT in EGFR-mutant non-small cell lung cancer and 百利天恒's EGFR×HER3 dual antibody ADC iza-bren in extensive-stage small cell lung cancer [24][29] Summary by Sections Weekly New Drug Market Review - From March 16 to March 22, 2026, the top five gainers in the new drug sector were 三生国健 (+23.14%), 旺山旺水 (+12.90%), 派格生物医药 (+10.29%), 海思科 (+10.12%), and 泽璟制药 (+9.53%). The top five losers were 迈博药业 (-25.71%), 开拓药业 (-24.81%), 轩竹生物 (-14.00%), 药捷安康 (-10.50%), and 亚虹医药 (-10.30%) [19][21] Weekly Focus on Recommended Stocks - The report suggests focusing on stocks with potential catalysts, including: 1. Companies with overseas data catalysts: 贝达药业, 映恩生物, 和黄医药 2. Companies with MNC certification and high certainty for future overseas volume: 三生制药, 联邦制药, 科伦博泰 3. Potential heavyweights for overseas licensing by MNC: 复宏汉霖, 石药集团, 益方生物 4. New innovative drug technology breakthroughs: small nucleic acids, in vivo CAR-T, fat reduction and muscle gain, autoimmune CAR-T/dual antibodies, gene therapy [2][23] Weekly New Drug Industry Analysis - The report emphasizes the significance of the ELCC 2026 conference, where key data from clinical trials will be presented, showcasing the efficacy of new treatments in lung cancer [3][24] Weekly New Drug Approval & Acceptance Status - No new drug or new indication approvals were reported this week, but three new drug or new indication applications were accepted [31] Weekly New Drug Clinical Application Approval & Acceptance Status - A total of 63 new drug clinical applications were approved, and 27 new drug clinical applications were accepted this week [33]

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 3.17%, ranking 22nd among 31 primary industries, underperforming the CSI 300 index which fell by 1.25% [6][17] - The valuation of the pharmaceutical and biotechnology industry as of February 6, 2026, is a PE (TTM overall method, excluding negative values) of 29.57x, down from 30.31x in the previous period, indicating a downward trend below the average [6][22] - The top three sub-industries in terms of PE (TTM overall method, excluding negative values) are vaccines (46.30x), hospitals (43.34x), and medical consumables (37.71x), while pharmaceutical distribution has the lowest valuation at 14.88x [22] Industry Trends - The focus in the global pharmaceutical market continues to be on GLP-1 targets, with Eli Lilly's tirzepatide establishing a leading position in the metabolic disease field due to its clinical value and commercialization performance [9] - The collaboration model between multinational pharmaceutical companies and Chinese biopharmaceutical firms is evolving towards "platform capabilities + multi-project combinations," highlighting the long-term strategic value of underlying innovative capabilities such as sustained delivery technology and peptide R&D platforms [9] - The investment logic in the industry is shifting from single blockbuster products to platform-based, matrixed approaches that extend into critical supply chain segments [9] Investment Recommendations - Focus on innovative pharmaceutical companies with "core technology platforms + diversified pipelines," as their ability to derive multiple values from platforms and realize cross-border cooperation milestones will be a key advantage [9] - Pay attention to industry chain segments benefiting from drug long-acting and oral trends, including complex formulation processes, high-end delivery technologies, and related peptide CDMO fields [9] - In the context of strong global R&D and production demand, peptide CXO companies that are active in cross-border collaborations, have balanced customer structures, and possess solid compliance systems will continue to share in the industry's high prosperity dividends [9]

Investment Rating - The investment rating for the industry is "Positive" and the rating has been maintained [1] Core Insights - The pharmaceutical and biotechnology industry index experienced a decline of 3.17%, ranking 22nd among 31 primary industries, underperforming the CSI 300 index which fell by 1.25% [6][17] - The valuation of the pharmaceutical and biotechnology industry as of February 6, 2026, is a PE (TTM overall method, excluding negative values) of 29.57x, down from 30.31x in the previous period, indicating a downward trend below the average [6][22] - The top three sub-industries in terms of PE (TTM overall method, excluding negative values) are vaccines (46.30x), hospitals (43.34x), and medical consumables (37.71x), while the median is 32.64x, with pharmaceutical distribution having the lowest valuation at 14.88x [22] Industry Trends - The focus in the global pharmaceutical market is on GLP-1 targets, with Eli Lilly's Tirzepatide establishing a leading position in the metabolic disease field due to its clinical value and commercialization performance [9] - The collaboration model between multinational pharmaceutical companies and Chinese biopharmaceutical firms is evolving towards "platform capabilities + multi-project combinations," highlighting the long-term strategic value of underlying innovative capabilities such as sustained delivery technology and peptide R&D platforms [9] - The investment logic in the industry is shifting from single blockbuster products to platform-based, matrixed approaches, and key supply chain segments [9] Investment Recommendations - Focus on innovative pharmaceutical companies with "core technology platforms + diversified pipelines," as their ability to derive multiple values from platforms and achieve cross-border collaboration milestones will be a key advantage [9] - Pay attention to industry chain segments benefiting from drug long-acting and oral trends, including complex formulation processes, high-end delivery technologies, and related peptide CDMO fields [9] - In the context of strong global R&D and production demand, peptide CXO companies that are active in cross-border collaborations, have balanced customer structures, and possess solid compliance systems will continue to share in the industry's high prosperity dividends [9]

Core Viewpoint - Fuhong Hanlin (02696) has seen its stock price increase by over 24% in February, with a recent rise of 5.67% to HKD 70.85, driven by a strategic partnership with Eisai Co., Ltd for the commercialization of the anti-PD-1 antibody, Surufatinib, in Japan [1] Group 1: Partnership Details - Eisai and Fuhong Hanlin have entered into an exclusive commercialization agreement for Surufatinib in Japan, which includes a USD 75 million upfront payment, potential regulatory milestone payments up to USD 80.01 million, and sales milestone payments up to USD 233.3 million [1] - Fuhong Hanlin will also receive a double-digit percentage royalty based on product sales [1] Group 2: Strategic Decisions - Fuhong Hanlin's CEO, Dr. Zhu Jun, indicated that the company has been strategically preparing for the Japanese market for three years, initially planning to independently launch and commercialize the product [1] - The decision to partner with Eisai was influenced by the "very sincere" offer made by Eisai, leading to a shift from their original plan [1]

Core Viewpoint - Fuhong Hanlin (2696.HK) has seen a significant stock price increase of over 8% on February 10, with a total rise of 30% over six days, indicating a reversal trend and a current market value of HKD 39.6 billion [1] Group 1: Company Developments - Fuhong Hanlin has completed the full circulation of H-shares, which is expected to enhance its global strategy and attract more international investors, benefiting long-term development and shareholder interests [1] - At the JPM 2026 conference, the company showcased its "Globalization 2.0" strategy, outlining future innovation pipeline and development plans, with over 40 new clinical research applications expected to be approved in the next five years [1] - By 2030, the company anticipates having over 20 products launched globally, with 15 expected to enter the European and American markets [1] Group 2: Product Pipeline and Collaborations - The company plans to commercialize more Antibody-Drug Conjugates (ADCs), bispecific antibodies, and T-cell engagers (TCEs), targeting four major therapeutic areas: oncology, autoimmune diseases, metabolism, and central nervous system disorders [1] - Fuhong Hanlin has entered into an exclusive commercialization agreement with Eisai Co., Ltd. for the anti-PD-1 antibody, Surulitinib, in the Japanese market, which includes an upfront payment of USD 75 million and potential milestone payments totaling up to USD 800.1 million, along with royalties based on product sales [1]

Core Viewpoint - Fuhong Hanlin (2696.HK) has seen a significant stock price increase of over 8%, with a total rise of 30% over six days, currently trading at HKD 72.7, with a market capitalization of HKD 39.6 billion [1] Group 1: Company Developments - Fuhong Hanlin has completed the full circulation of H-shares, which is expected to enhance liquidity and support its globalization strategy, thereby unlocking long-term investment value [1] - The company showcased its "Globalization 2.0" strategy at the JPM 2026 conference, outlining its future innovation pipeline and development plans [1] - Over the next five years, Fuhong Hanlin anticipates more than 40 new clinical research applications to be approved, with over 20 products expected to be launched globally by 2030, 15 of which are projected to enter the European and American markets [1] Group 2: Product Pipeline and Collaborations - The company plans to commercialize more Antibody-Drug Conjugates (ADC), bispecific antibodies, and T-cell engagers (TCE) across four therapeutic areas: oncology, autoimmune diseases, metabolism, and central nervous system disorders [1] - Fuhong Hanlin has entered into an exclusive commercialization agreement with Eisai Co., Ltd. for the anti-PD-1 antibody, Surulitinib, in the Japanese market, along with a joint exclusive development and production licensing agreement [1] - Eisai will pay Fuhong Hanlin an upfront payment of USD 75 million, with potential regulatory milestone payments up to USD 80.01 million, and sales milestone payments up to USD 233.3 million; Fuhong Hanlin will also receive a double-digit percentage royalty based on product sales [1]

Group 1 - The core viewpoint of the article highlights the significant rise in the stock price of Fuhong Hanlin (02696), which has increased over 24% in the month, with a current price of 70.85 HKD and a trading volume of 338 million HKD [1] Group 2 - On February 5, 2023, Eisai Co., Ltd. and Fuhong Hanlin announced an exclusive commercialization agreement for the anti-PD-1 antibody, Surufatinib, in the Japanese market, along with a joint exclusive development and production licensing agreement [1] - Eisai will pay Fuhong Hanlin an upfront payment of 75 million USD, with potential regulatory milestone payments up to 80.01 million USD, and sales milestone payments that could reach up to 233.3 million USD [1] - Fuhong Hanlin will also receive a double-digit percentage royalty based on product sales [1] Group 3 - On February 6, 2023, Dr. Zhu Jun, the Executive Director and CEO of Fuhong Hanlin, stated that the company had been strategically preparing for the Japanese market for three years and had formed a local team [1] - The decision to collaborate with Eisai instead of pursuing independent commercialization was influenced by the "very sincere" offer made by Eisai [1]

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The proportion of driver gene-negative non-small cell lung cancer (NSCLC) patients is approximately 31% in both China and the United States, indicating a significant market opportunity for treatments targeting this demographic [2][15] - The estimated market size for immune drugs used in first-line treatment of driver gene-negative NSCLC is projected to be around 7.5 billion CNY (approximately 1.1 billion USD) in China and 18 billion CNY (approximately 2.7 billion USD) in the United States by 2030 [2] - The current first-line treatment for advanced driver gene-negative NSCLC primarily relies on PD(L)-1 inhibitors combined with chemotherapy, but there are limitations in long-term efficacy and options for patients intolerant to chemotherapy [3] Summary by Sections Section 1: NSCLC Global Overview - Lung cancer is the leading cancer type globally, with new cases accounting for approximately 12% of all cancer cases in 2022, translating to about 2.5 million new lung cancer cases [10] - In China, lung cancer represents about 22% of new cancer cases, with approximately 1.06 million new cases in 2022 [10] Section 2: Market Potential for Driver Gene-Negative NSCLC - The report highlights the significant market potential for immune therapies in treating driver gene-negative NSCLC, with a focus on the limitations of current treatment options [2][3] Section 3: Next-Generation Immunotherapy Approaches - The report discusses the advancements in dual (multi) antibody therapies and immune-oncology (IO) combined with antibody-drug conjugates (ADC), emphasizing their potential to improve treatment outcomes for patients with driver gene-negative NSCLC [5][8] - The clinical data supporting these new therapies is expected to catalyze further investment and development in this area [5] Section 4: Treatment Guidelines Comparison - The report compares treatment guidelines for driver gene-negative NSCLC between the United States and China, noting differences in treatment stratification and recommended therapies [32][34] - The U.S. guidelines emphasize PD-L1 expression levels, while Chinese guidelines focus more on performance status (PS) [32][34] Section 5: Future Catalysts - Key upcoming clinical data releases and studies are highlighted as potential catalysts for investment opportunities in the sector, particularly regarding dual antibodies and ADC therapies [5][8]